• Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor for MASH, reinforcing its focus on next-generation liver disease therapies.
• This deal adds a complementary clinical-stage asset alongside Rezdiffra’s early commercial traction, potentially broadening Madrigal’s role in MASH treatment combinations and care pathways.
• We’ll now explore how the Pfizer ervogastat license could reshape Madrigal’s investment narrative built around Rezdiffra-centered MASH leadership.

We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Madrigal Pharmaceuticals Investment Narrative Recap

Madrigal’s story still centers on Rezdiffra as a first-in-class MASH therapy, with investors needing confidence in its clinical profile, payer access and commercial execution. The Pfizer ervogastat license strengthens the combination-therapy narrative but does not materially change that the key near term catalyst remains Rezdiffra’s continued uptake, while the biggest risk is the company’s dependence on this single asset and the associated earnings volatility if performance disappoints.

The most relevant recent announcement here is Goldmans reaffirmation of its Buy rating after Madrigal highlighted Rezdiffra’s early commercial reach to 29,500 patients and over 10,000 prescribers, alongside the ervogastat deal. That context ties the Pfizer agreement directly to the existing MASH franchise, reinforcing Rezdiffra-centered leadership as the main driver of sentiment and future catalysts even as the pipeline broadens.

Yet behind the growth story, investors should also be aware of rising SG&A and R&D commitments that could...

Madrigal Pharmaceuticals' narrative projects $2.5 billion revenue and $822.9 million earnings by 2028.

Uncover how Madrigal Pharmaceuticals' forecasts yield a $603.47 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Six Simply Wall St Community fair value views span roughly US$460 to about US$1,828 per share, reflecting very different expectations for Madrigal. Against this wide range, Madrigal’s continued reliance on Rezdiffra as a single lead asset gives you a clear focal point for stress testing your own assumptions about the company’s future performance.

Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Build Your Own Madrigal Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.